NZ244985A - Peptide compounds, preparation and pharmaceutical compositions thereof - Google Patents
Peptide compounds, preparation and pharmaceutical compositions thereofInfo
- Publication number
- NZ244985A NZ244985A NZ244985A NZ24498592A NZ244985A NZ 244985 A NZ244985 A NZ 244985A NZ 244985 A NZ244985 A NZ 244985A NZ 24498592 A NZ24498592 A NZ 24498592A NZ 244985 A NZ244985 A NZ 244985A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- radical
- compound
- vherein
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
New Zealand Paient Spedficaiion for Paient Number £44985
7 1 '■
' '-.or
■' . i
Priority Cctels): .W.W.^
Con^iuie Verification Filed:
Clas*- Jsfr,.9*\.CfiYfi^Lo*.. AW.*r.¥A\£*U
27-W1993'
Publication Date:
P.O. JNo! .... ,. . . ,
\ i vt **• r- * ,*• • *
,w ^YiAVi/S**u£
r~"'
-2 !i:V 1992
RH-L.vtD
No.: Date:
NEW ZEALAND PATENTS ACT, 1953
COMPLETE SPECIFICATION PEPTIDES
We, SANDOZ LTD., 35 Lichtstrasse, CH-4002 Basle, Switzerland, a Swiss Body Corporate hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:-
- 1 -(followed by page la)
24498
- la -
PEPTIDES
The present invention relates to peptides having pharmaceutical utility, processes for their production, pharmaceutical compositions comprising them and their use as pharmaceuticals.
More particularly the present invention provides a compound of formula I
R is hydrogen, an amino protecting group or optionally ring substituted benzyloxy,
Ai is Val, Leu, Ala, lie or trimethylsilyl-Ala,
A2 is Phe or Tyr,
n is 0 or 1,
A3 is a direct bond, Val, Leu, Ala, lie, trimethylsilyl-Ala or a divalent radical of formula (a)
R-lAi-Aj]n-Aj-A«-X-A5
(I)
vherein
(a)
wherein ring A is optionally substituted by hydroxy or C1_4alkoxy,
> -
244985
is a direct bond or a divalent radical of formula (b)
-N - CH-CO-
I !
Ri Yx
(b)
wherein R! is hydrogen or C1_4alkyl, and
Yi is the residue attaching to the a-carbon atom of an a-amino acid and is optionally protected, -CH2-CH2-N(Ci_4alkyl)2, imidazol-2-yl-methyl, benzimidazol-2-yl-methyl, 1H-1,2,A-triazol-3-yl-methyl, pyrazol-3-yl-methyl, indazol-3-yl-methyl or a radical of formula (c) or (d)
(c)
or
<d)
wherein each of R2 and R3, independently, is hydrogen,
halogen, C1_4alkyl, CF3 or trityl, at most one of R2 and R3 being H, and each of R« and R5 independently is hydrogen,
Ci_4alkyl, hydroxy, Ci_4alkoxy, CF3, phenyl or halogen, at most one of R4 and R5 being H, or A3 and A4 form together a radical of formula (aa)
-NH-CH - CO-N - CH-CO-
(aa)
Ri.
Ri wherein Yi is as defined above and Rx and Rla form together -(CH2)„- wherein m is 2, 3, A or 5, and
' ) / /■' L.
H
3 -
1) X is a divalent radical of formula (e^
(ei)
wherein R6 is H or Ci_«alkyl,
and A5 is CF3; a radical -CHj-Xx-Yj vherein Xi is 0 or S and Y3 is heteroaryl; a radical -CH2-Yj; or a radical of formulae (k) to (0)
-CH2-X1-CO-Y4 f
-CHj-Xi u 0
^11
(k)
(1)
R,
\ R
^11
or
-CH2-X1V 3 ^
V'\
u 1
(m) (0)
wherein
X] is as defined above,
Y4 is tri-(C1_<alkyl)methyl or a residue ring B is pyridyl,
- A -
244985
ring C is phenyl or pyridyl,
each of R7 and Re independently is Ci.^alkyl, Cj.^alkoxy, CF3, halogen, nitro or cyano, and each of R9, R10 and R:x independently is nitro, cyano, CF3, carbamoyl, C02Ri2, -CH=CH-CN or -Cf^CHCOjRu wherein R12 is Ci _6alkyl,
or X is a divalent radical of formula (e2)
2)
OC, .alkvl
V
'1
alkyl
C0oC, „alkvl
C '
wherein Rg is as defined above,
when A5 is H, or X is a divalent radical of f-ormula (f),
<e2)
3)
(f)
wherein is as defined above,
and A5 is -Z1-Z2-Y2 wherein each of l\ and I2 independently is a direct bond or an a-amino acid residue and Y2 is NH?, Ci_4alkylamino, di-(Ci_4dlkyl)amino or a heterocyclic radical attached by a nitrogen to Z2,or a radical of formula (k) to (0) as defined above, or OR13 or NR14R15 wherein Rj3 is Ci.j^alkyl optionally substituted by OH or interrupted by 0 and each of R14 and R15 is independently hydrogen, Ci_i2alkyl, C5_7cycloalkyl or benzyl, or X is a divalent radical of formula (g)
244985
and As is -Zi-Z^-Yj as defined above, or A) X is a divalent radical of formula (h) or (j)
(h) (j)
wherein Rg is as defined above,
and A5 is a radical of formulae (k) to (o), -CH2-Y3 or
-CH2-X1-Y3 as defined above,
with the provisos that only one of A3 and A4 can be a direct bond when n is 0, and each of A3 and A4 is other than a direct bond when n is 1,
or a physiologically-hydrolysable and -acceptable ester or amide thereof,
in free form, in salt form or in the form of a complex.
Examples of protecting groups as R are e.g. disclosed in "Protective Groups in Organic Synthesis", T. V. Greene, J.Viley & Sons NY (1981), 219-287, for example acyl such as acetyl, methoxy-succinyl, hydroxysuccinyl or benzoyl optionally substituted on the phenyl ring with e.g. p-methoxycarbonyl, p-methoxy or p-nitro; alkoxycarbony1 such as t-butyloxycarbonyl; arylmetho-xycarbonyl such as 9-fluorenylmethoxycarbonyl or benzyloxy carbo-nyl optionally substituted on the phenyl ring with p-methoxy, p-nitro, p-chloro or m-phenyl; arylmethyl such as benzyl optionally ring substituted with p-methoxy, p-nitro or p-chloro; or
24
- 6 - 100-7821
vith p-methyl or p-methoxy, or naphthylsulfonyl optionally ring substituted vith e.g. amino or di(Ci.^alkyljamino.
Vhen R is ring substituted benzyloxy, it is preferably benzyloxy substituted vith hydroxy or Ci_4alkoxy. Preferably R is unsubstituted benzyloxy.
Halogen is preferably fluorine or chlorine.
Uhen A3 is a substituted radical of formula (a) it is preferably substituted by Ci.^alkoxy, preferably in para to -C=0.
By a-amino acid is meant a naturally occurring or commercially available or non natural a-amino acid or an optical isomer thereof. A non natural a-amino acid is an a-amino acid vhich is not incorporated into a protein under mRNA direction, e.g. 3-Nal, a fluoro-a-amino acid such as fluoroalanine, trimethylsilyl-Ala or an a-amino acid such as
Wr*
I
m
(CH2}m
COCH
w^\—ch-cooh wherein n: is an integer from 1 to 6 and n2 is an integer from 1 to 12.
Protecting groups vhich may be present in Y. are groups which protect the 0, S or N functionality in the side chain amino groups of an a-amino acid. N-protecting groups are e.g. as disclosed above for R, or C3_5alkyl such as isopropyl, formyl, a sugar residue such as 1-deoxy-fructosyl or a-glucosyl(1-4)-
^ / *~* t
100-7821
deoxyfructosyl, dihydroxy-C3_6alkyl such as dihydroxypropyl, C5_7cycloalkyl such as cyclohexyl or tropinyl. 0- and S-protecting groups for hydroxy and thiol functionalities are known and may be e.g. methyl, t.-butyl or benzyl.
Vhen Y2 is a heterocyclic radical, it may be e.g. a 5 or 6 membered ring, e.g. piperidino or pyrrolidinyl.
Examples of heteroaryl as Y3 include e.g. 5-, 6- or 7-merr.bered unsaturated heterocyclic radicals, comprising at least one nitrogen and optionally further heteroatoms such as N, 0 or S. Preferably Y3 is heteroaryl comprising from 1 to A nitrogen atoms, e.g. pyridyl, triazolyl, tetrazolyl, triazin-dionyl.
In ring B of radical (o), the nitrogen atom may be in o-, m- or para. Vhen ring C in radical (k) is pyridyl, it may be 3-, 4- or
-pyridyl.
Radicals (e^, (e2), (f), (g) and (j) are derived from Asp and comprise one asymetric carbon atom and radical (h) comprises two asymetric carbon atoms and accordingly they lead to optical isomerism. It will be understood that the present invention includes all individual isomeric forms and diastereoisomers as well as mixtures, e.g. racemates, unless otherwise stated.
Radical of formula (ej) attached to A5 which is hydrogen may exist in both cyclic as well as in non-cyclic form e.g. as follows:
0
8
100-7821
It is to be understood that where tautomeric forms occur, the present invention embraces both lactol and oxo-carboxylic acid forms, i.e. although compounds of formula I wherein X is a radical of formula (ex) are defined for convenience by reference to the oxo-carboxylic acid form only, the invention is not to be understood as being in any way limited by the particular nomenclature or graphic representation employed. Similar considerations apply in relation to starting materials exhibiting lactol/oxo-carboxylic acid tautomerism as hereinafter described.
The same considerations also apply to radical of formula (h) which may exist in both linear and cyclic form as follows:
and to compounds of formula I comprising a radical of formula (h) and to the corresponding starting materials.
By the term "physiologically-hydrolysable and -acceptable esters or amides" are meant esters and amides which are hydrolysable under physiological conditions to yield alcohols or amines which are themselves physiologically acceptable, i.e. which are nontoxic at the desired dosage levels.
Such esters or amides are obtained by esterification or amidation, respectively, of a compound of formula I wherein X is a radical bearing a carboxy group. Such esters include esters with an aliphatic or alicyclic alcohol or polyol having 1 to 12 carbon atoms. Such amides include amides with aliphatic amines, e.g. Ci_4alkyl amine, Cj^alkoxy-Ci^alkyl amine such as
OH
0
0
«
- 9 - 100-7821
fj-methoxy-ethyl amine, or aniline.
The compounds of formula I may exist e.g. in free form, acid addition salt form or in the form of complexes thereof. Acid addition salts may be formed vith e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates. Salt forms may also include those obtainable vith the carboxylic group present in compounds of formula I, e.g. alkali metal salts such as sodium or potassium, or substituted or unsubstituted ammonium salts. Complexes are e.g. formed from compounds of formula I on addition of inorganic substances, e.g. inorganic salts or hydroxides such as Ca-and Zn-salts, and/or an addition of polymeric organic substances.
In the compounds of formula I, the following significances are preferred either individually or in any combination or subcombination:
1. R is an amino protecting group or benzyloxy, preferably an amino protecting group. R is preferably benzyloxy when n is 0 and A3 is a radical of formula (a).
2. Each of A3 and A4 are other than a direct bond.
3. n is 0.
4. A3 is a radical of formula (a) when n is 0.
. A3 is a direct bond, Val, Leu, Ala, lie or trimethylsily-Ala.
6. Ri is hydrogen or methyl, preferably hydrogen.
7. Yi is the residue attaching to the a-carbon atom of an a-ami-no acid selected from Ala, Leu, His, Phe, Met, Trp, trimethylsilyl-Ala and optionally side chain protected Arg, Orn and Lys, or Yi is a radical of formula (c).
100-7821
8. A3 and A4 may also form together a radical of formula (aa) vhen n is 0.
9. m is 2 or 3.
. X is a radical of formula (ei) and A5 is other than H.
11. X is a radical of formula (g).
12. X is a radical of formula (h) or (j).
13. R€ is hydrogen or methyl, preferably hydrogen.
14. Zx in A5 is the residue of a natural a-amino acid, preferably of an aromatic/heterocyclic a-amino acid, particularly Pro.
. Z2 in A5 is the residue of a natural a-amino acid, preferably an aliphatic a-amino acid, particularly an aliphatic a-amino acid without further functional group, most preferably Val.
16. X is a radical of formula (ex) optionally esterified or amidated and A5 is a radical of formula (k), (1) or (o).
17. X is a radical of formula (ei), (h) or (j) optionally esterified or amidated and A5 is -CH2-X1-Y3, preferably -CH2-S-Y3, or -CH2-Y3.
18. X is a radical of formula (h) or (j) optionally esterified or amidated and As is (k).
19. X is a radical of formula (j) optionally esterified or amidated and A5 is a radical of formula (m).
. Radical of formula (m) is monosubstituted, preferably in
244 98
- ii -
para, more preferably it is 4-nitrophenyl.
21. All a-amino acid residues present except X have the L configuration. X has the D or L configuration.
22. The asymetric carbon in (h) bearing the OH group has the configuration S. Preferably the asymetric carbon in (j) bearing R6 has the configuration R.
In a series of specific embodiments, the present invention also provides a compound of formula I wherein n is 0, A3 is a direct bond, Val, Leu, Ala, lie or trime-thylsilyl-Ala, A< is as defined above, or A3 and A« form together a radical of formula (aa) as defined above, and i) X is a radical of formula (ex) or (f) and A5 is a radical of formula (k), (1) or (m) wherein Xj is 0,
ii)X is a radical of formula (g) and A5 is -Z!-Z2-Y2,
or iii) X is a radical of formula (j) and A5 is a radical of formula (k), (1) or (m) wherein Xj is 0.
The present invention also provides a process for the production of a compound of formula I, which process comprises:
a) removing at least one protecting group from a compound of formula I in protected form or adding a protecting group R at the N-terminal group of a compound of formula I; or b) converting one compound of formula I into another compound of formula I; or c) coupling together by an amide bond two peptide fragments,
c 4
each of vhich contains at least one amino acid in protected or unprotected form and one peptide fragment containing a radical of formula (e:) to (j) as defined above, the peptide fragments being such that a protected or unprotected peptide having the sequence according to formula I above is obtained and, if necessary, removing the protecting group or groups from a compound of formula I in protected form; or d) for the production of a compound of formula I vherein X is a radical of formula (e:) or (h) and A5 is a radical of formula
(k), (1) or (o) or -CH2-X:-Y3, reacting a compound of formula III
vherein R, A: to A4 and n are as defined above, X' is a radical of formula (e;) or (h), and Za is a leaving group, e.g. halogen,
vith a corresponding phenol, thiophenol or HXi-pyridine or an acid of formula HXi-C0-Y?or a functional derivative thereof or HX!-Y3; or e) for the production of a compound of formula I
MAi-A; ]n-A3-A4-X'-CH2-Za
(III)
H 0
(I)
C02RI6
vherein R, Ax to As and n are as defined above and R16 is a Ci_i2 aliphatic or alicyclic residue, oxidizing a compound of formula V
100-7821
H OH
R-[Ai-A2]n-A3-A4-N
A5
(V)
COjRi 6
vherein R, A: to A5, 11 and R16 are as defined above,
and recovering a compound of formula I thus obtained in free or salt form or in the form of a complex.
Processes (a) to (e) above may be carried out in accordance vith standard techniques knovn in the art.
The removal of a protecting group in process step (a) may also include the removal of R on the N-terminal group of a compound of formula I. For example, vhen R is benzyloxy carbonyl, this group may be removed by hydrogenation in the presence of a catalyst, e.g. Pd.
In accordance vith process step (b) for example, for the production of a compound of formula I vherein X comprises a carboxy group, a compound of formula I vherein X comprises an esterified or amidated carboxy group may be hydrolysed. Such hydrolysis may be effected by treatment vith an appropriate alkali or by acid hydrolysis, for example in the presence of trifluoroacetic acid.
Furthermore, in accordance vith process step (b), for the production of a compound of formula I vherein X comprises an esterified or amidated carboxy group, a compound of formula I vherein X comprises a carboxy group or an esterified caboxy group may be (trans) esterified or amidated. Such ester formation or amidation may be carried out using any of the techniques knovn in the art, for example converting the carboxy group in a functional
9 /
14 -
100-7821
reactive group, e.g. a corresponding carbonyl halide or anhydride, or using a compound of formula I vherein X is a radical of formula (h) in the lactone form, and reacting such group vith the selected alcohol or amine.
In accordance vith a further embodiment of process step (b), for the production of a compound of formula I vherein X is a radical of formula (g), a compound of formula I vherein X is a radical of formula (e^) or (e2) and Ac, is H may be reacted vith a compound of formula II
H2N-NH-C0-A5 (II)
vherein A5 is as defined above. This process may be carried out in analogy to the knovn techniques used for the preparation of semi carbazones.
A compound of formula I vherein X is a radical of formula (e:) may also be converted in accordance vith knovn techniques into a compound of formula I vherein X is a radical of formula (e2) and vice versa.
Process step (c) may be carried out by the techniques knovn in the art of peptide chemistry. By peptide fragment comprising a radical of formula (e:) to (j) is also meant the radical itself bearing a protecting group on the -NR6- moiety and an appropriate ending, e.g. A5 or CH2-Za, on the other end.
Process step (d) may conveniently be effected using a Dess-Martin reagent, e.g. in the presence of a base or a halogen-precipitating silver salt, or according to the Svern oxidation procedures.
Vhere desired, in these reactions, protecting groups may be used for functional groups vhich do not participate in the reaction.
100-7821
These rr.ay be e.g. amino protecting groups, carboxy protecting groups, acetal groups etc. When the desired reaction is complete, the protecting groups may then be removed.
Each of the above processes may be carried out using starting materials in the form of one or other of the individual optical isomers or in the form of mixtures [relating to the asymetric carbons present in radicals of formulae (e:) to (j) as X or in such a radical precursor]. Conveniently the starting materials are used as S- or R-enantiomers to produce a compound of formula I vherein the asymetric carbon in radicals of formulae (ej) to (j) has the S or R configuration, respectively.
The starting materials used in process steps (d) or (e) may be prepared in analogy vith process step (c).
Insofar as the production of the starting materials is not particularly described, the compounds are known or may be prepared analogously to methods knovn and practiced in the art.
The following examples are illustrative of the invention. All temperatures are in °C.
The following abbreviations are used:
THF
tetrahydrofuran
TFA
trifluoroacetic acid
MeOH =
methanol
EtOAc =
ethyl acetate
DCC
dicyclohexylcarbodiimide
HOBT =
hydroxybenzotriazole
Z
benzyloxycarbonyl r. t. =
room temperature
Fmoc =
9-fluorenylmethoxycarbonyl a
amorph
100-7821 C 4
EXAMPLE 1: Z-Val-Het-Asp(OH)-H
Z-Val-Met-Aspartic aldehyde dimethyl acetal-ft-tert.butyl ester (1.17 g) is taken up in CH:C12 (150 ml), TFA (15 ml) and water (1 t,1) added and stirred for 2,5 hrs at r.t. The solvent is evaporated, toluene added twice and evaporated again. The crystalline residue is dissolved in water (60 ml) upon heating, decanted from some undissolved material and crystallized at 5 affording the first crop of the product: m.p. 117 °. All mother liquors are collected and chromatographed (Si02, acetone/hexane/-EtOAc 60/40/0.5) to give a second crop of product, crystallizing upon trituration vith water.
EXAMPLE 2: Z-Val-Het-Asp(OH)-S Semicarbazone
Compound of Example 1 (0.27 g, 0.55 mmol) in MeOH (2 ml) is combined vith semicarbazide, HCl (0.6 ml of 1 molar solution), then 5 drops of pyridine are added. The product crystallizes after 10 min. at r.t.: m.p. 233 - 235 °.
EXAMPLE 3: Z-Val-Met-Asp(OH)-H semicarbazonyl-Pro-Val-N(CH3)2
Compound of Example 1 (0.48 g, 1 mmol) is dissolved in a mixture of MeOH (2 ml) water (0.5 ml) and 3 drops of pyridine. N-(hydrazinocarbonyl)-Pro-Val-N(CH3)2 (0.3 g, 1 mmol) is dissolved in MeOH (1 ml), water (2 ml) and 3 drops of 2N HCl.
Both solutions are combined and warmed for 2 min. at 40 - 50 °. The product crystallizes upon cooling: m.p. 118 - 120 °.
By repeating the procedure of Example 1, using the corresponding starting materials, following compounds may be prepared:
Example 4
Z-Val-Phe-Asp(0H)-H
244
Example 5 Z-Val-His-Asp(OH)-H
By repeating the procedure of Example 2 or 3 respectively, using the corresponding starting materials, following compounds of formula IA
H ..
Z-A3-A4-N—r^5^fJ^NN^NHA5 (IA)
XC02H 0
wherein A3, A4 and A5 are as defined below, may be prepared.
Example
Aj
A«
As
H.P.
°C
6
Val
Phe
H
a
7
Val
His
H
150
8
Val
Phe
Pro-
-Val-
-N(CH3)2
126-
129
9
Val
His
Pro-
<—1 >
1
-N(CH3)2
Ala-Tyr-Val
Phe
H
205
EXAMPLE 11: (3S)-3-(Z-valyl-histidyl )-aniino-5-(2,6-dimethy1 benzoyloxy)-4-oxo pentanoic acid
(3 S,4RS)-3-(Z-Val-His)amino-4-hydroxy-5-(2,6-dimethylbenzoyloxy) pentanoic acid tert.-butyl ester (0.6 mmol) is treated with Dess-Martin reagent (0.77 mmol) in CH2Cl2 (4 ml) for 45 min. and filtered. Aceton and 0.5 N NaOH are then added and aceton is evaporated. The residual crystalline material is washed vith H20, acidified with 10 X tartaric acid and extracted with EtOAc. The combined EtOAc extracts affords after evaporation the tert. butyl ester of the product as yellow crystals. These are dissolved in CH2C12 (4 ml), TFA (4 ml) is added and the mixture is stirred at r.t. for 15 min. The mixture is evaporated to dryness and chromatographed (Si02, aceton/hexane/EtOAc 60/40/1) affording the product as slightly colored crystals.
2449
EXAMPLE 12: (Z-valyl-alanyl)-(3R,4S)-3-amino-4-hydroxy-5-
(2,6-dichlorbenzoyloxy) pentanoic acid ethyl ester
(Z-valyl-alanyl)-3R,4S)-3-amino-4,5-dihydroxy pentanoic acid ethyl ester and 4-dimethylaminopyridine are dissolved in pyridine and 2,6-dichlorobenzoyl chloride is added dropvise. The reaction mixture is stirred overnight at room temperature, then ice and vater are added and the mixture is extracted vith AcOEt. The organic layer is washed vith vater, then vith NaCl solution,
dried over Na2S04, filtered, evaporated, and the crude product is chromatographed to give the title compound.
The (3R.4RS) derivative of the title compound may be prepared as follovs:
Z-Val-Ala-OH (0.26 mmol), DCC (53 mg, 0.26 mmol) and HOBT.HjO (39 mg, 0.26 mmol) are dissolved in THF/DMF (2 ml/2 ml) and stirred for 5 min., before (3S,4RS)-3-amino-4-hydroxy-5(2,6-dimethylbenzoyloxy)-pentanoic acid tert.butyl ester (87 mg, 0.26 mmol) in THF (2 ml) is added. The reaction mixture is stirred overnight at r.t., evaporated and chromatographed (Si02, Et0Ac/Me0H/NH3 95/5/0.5) to afford the (3R,4RS) title compound.
EXAMPLE 13: (Z-valyl-alanyl)-(3R)-3-amino-4-oxo-5-(2>6-dichloro-benzoyloxy) pentanoic acid ethyl ester
Dimethylsulfoxide in CH2Cl2 is added dropvise to a solution of oxalyl chloride in CH2C12 at -50°C. After 15 min., a solution of compound of Example 12 in CH2C12 is added dropvise and the reaction mixture stirred for 1 hour at -40°C. Triethylamine is added and stirring is continued for 3 hours at room temperature. Vater is then added and the reaction mixture extracted vith CH2C12. The organic layer is vashed vith NaHCOj solution and
V
19 -
100-7821
N'aCl solution, dried over Na2S04, filtered and evaporated. The residue is chromatographed yielding the title compound.
By repeating the procedure of Examples 1-3 and 11 to 13, using the corresponding starting materials, following compounds of formula IB
0
(IB)
X
vherein A3, A4, Rx and Ry are as defined belov, may be prepared.
EXAMPLE A3 A<
14 Val Phe
Val His
16 Val His
17 Val His
(l-trityl)
18 Val His
19 Val His
Val His
21 Val His
(2-CF3)
22 Val Trp
23 TriMe-silyl- His
Ala
24
Ry Rx lap0 c(MoOH) or M.P. °C (2)
H 2,6-diMe-benzoyl
H 2,6-diMe-benzoy1
H p-N02-phenyl H H a (2)
H 2,6-diCl-benzoyl
H 2,6-diCF3-benzoyl
H 2,6-diN02-benzoyl
H 2,6-diCF3-benzoyl
H 2,6-diCF3-benzoyl
H 2,6-diCl-benzoy1
H
2,6-diCl-benzoyl
EXAMPLE
26
27
28
29
Ala-Tyr-Val D-Val Val Val Val
Phe His Arg His His
Val
His
31
Ry R* [a]20 c(MeOli)
or H.I'. "C (?)
(I il a (2)
H 2,6-diCl-benzoyl 39.2° 1.21
H 2,6-diCl-benzoyl
C2H5 2,6-diCl-benzoyl 26.7° 1.02
H /N=3\ -18.0° 0.97
-N N
/=N\ „
H -N N -19.0 0.96
H
2,6-diCl-benzoy1
EXAMPLE Aj A4
32
Val
Orn
33
Val
Lys
34
Val
Ala
Val
His
36
Val
His
37
Val
His
38
Val
His
39
Val
His
40
Val
Ala
41
Val
Leu
42
Val
His
43
Val
His
<2-CF3)
44
Val
His
45
Val
His
46
Val
Lys
(Nc-iC3H7)
47
Val
Lys
(N'-iC3H7)
48
Val
Ala
49
Val
Ala
Ry Rx |al-'° c(MeOH)
D
or M.P. °C (2)
H 2,6-diCl-benzoyl
H 2 ,6-diCl-benzoy1
H 2,6-diCl-benzoyl
H Pivaloyl i . C4 H 9 2 ,6-d iCl-benzoy 1 ~ *"
n.CjoHii 2,6-diCl-benzoyl »*
benzyl 2,6-diCl-benzoyl >*
CH2CH2OH 2,6-diCl-benzoyl * »•
C2H5 2,6-diCl-benzoyl
H 2,6-diCl-benzoyl
H 2,6-diF-benzoyl
H 2,6-diCl-benzoyl
C2H5 H H
Pivaloyl
2,6-diCl-benzoyl 2,6-d iCl-benzoyl
>»*
o
0
1
oo fO
C1H5 2,6-diCl-benzoyl **
H 2,6-diCl-benzoyl >-T
t.C4H9 2,6-diCl-benzoyl
~t
■»
EXAMPLE
50 Val Ala
51 Val Ala
52 TriMe-silyl— His
Ala
53
V-N
'O s
54 Val Ala
55 TriMe-silyl- Ala
Ala
56 TriMe-silyl- Ala
Ala
Ry Rk 1 a|2 0 c(MeOH)
D
or M.P. °C (2)
C2H5 2,6-diCl-benzoyl
C2Hs CI
-co —
CI
C2H5 2,6-diCl-benzoyl
C2H5 2,6-diCl-benzoyl i.C3H7 2,6-diCl-benzoyl t.C4H9 2,6-diCl-benzoyl
2,6-diCl-benzoyl
NJ LtJ
ro
CO
ao
CTl
EXAMPLE A3 A4 Ry Rx |«J'° c(MeOH)
D
or M.P. °C (2)
57 TriMe-silyl Ala 2,6-diCl-benzoyl
Ala
* the compounds have the following configuration in the aspartyl moiety:
0
C02R,
* * the compounds have the R,S configuration in the aspartyl moiety.
100-782
EXAMPLE 58:
Z-His-Asp-CH2-0-C0—y Q
a)'0 = -20.3° c = 1 in MeOH
EXAMPLE 59:
CI
Fmoc-Val-His-Asp-O-CO—^ O
CI
EXAMPLE 60:
CI
C6H5-CB2-0 C0-His-Asp-CH2-0-C0—(o ci
[ctU0 = -21.5° c = 1.07 MeOH
EXAMPLE 61:
C1.
C6 H5 -CH2 -0 ^^CO-His-Asp-CHj-0-C0—( Q
h3co
CI
EXAMPLE 62:
h*'
? lk
—S02-Val-Ala-Asp-CH2-0-C0—v Oy
CI
By repeating the procedure of Examples 1-3 and 12-13 and using the corresponding starting materials, following compounds of formula IC
OH
* i 0 ic
Z-Val-A4-NH^1 ' '
CO- - R 2 y wherein A3 , Rx and Ry are as defined below, may be prepared
EXAMPLE
63
64
65
66
Ala Ala
Ala Ala
H
C2H5
t . C4 Hg -C2H4-OCH3
2,6-diCl-benzoyl CI
<0_^N
CI
2,6-diCl-benzoyl 2,6-diCl-benzoyl
R S
R
i z.s
244985
EXAMPLE 67: (3RS)-3-(Z-valyl-phenylalanyl)amino-4-oxo-6-
(p-nitrophenyl)-transhex-5-enoic acid tert.butyl ester
(3RS)-3-(Z-Vaiyl-phenylalanyl)amino-4-oxo-pentanoic acid tert.butyl ester-5-diethylphosphonate (0.2 g, 0.29 mM) is dissolved in THF (15 ml) at 5°C. NaH (25 mg, 0.59 mM) is added and the mixture stirred for 10 min. p-Nitrobenzaldehyde (0.18 g, 1.1 mM) in THF (2 ml) is added at O'C and the reaction mixture stirred for 45 min. at this temperature. The reaction mixture is poored on 5 % tartaric acid, extracted vith ethyl acetate, the organic phases dried over Na2S04, evaporated and the product purified by chromatography yielding the title compound.
EXAMPLE 68: Z-Val-Phe-Aspartic aldehyde dimethyl acetal-g-methyl ester
Z-Val-Phe-Asp(OH)-H (0.8 g) is dissolved in MeOH (25 ml) containing 8 X HCl, left at r.t. over night, evaporated to dryness and the residual crystals washed with ether, providing the title compound as white crystals. M.p.: 168 - 171 °.
Starting materials may be prepared as follows:
EXAMPLE 69: (3S)-3-(Fluorenylmethoxycarbonyl)anino-5-iodo-4-oxo butanoic acid tert.butyl ester
Triethylamine (1.3 ml, 9.6 mmol), followed be ethylchloroformiate (0.92 ml, 9.6 mmol) are added to (3S)-3-(fluorenylmethoxycarbo-nyljamino^-carboxy-butanoic acid tert.butyl ester (3.5 g, 8.5 mmol) in THF (60 ml) at - 10 °. After 10 min., a solution of dia-zomethane in ether is added slowly, and the reaction mixture stirred for 45 min. at 0 - 5 °. HCl (2N) in ether is added at 5 -10 0 until gas evolution has ceased. The reaction mixture is evaporated to dryness, taken up in acetone (50 ml) Nal (4 g) added
100-7821
and stirred for 1 hr at r.t. Ether (150 ml) is added, the reaction mixture filtered and evaporated. The residue is chromatographed (Si02, EtOAc/hexane), yielding the title compound as slightly yellow crystals.
EXAMPLE 70; (3S)-3-(Fluorenylmethoxycarbonyl)ainino-5(2,6-
dimethylbenzoyloxy)-4-oxo pentanoic acid tert.butyl ester
3S-3-(Fluorenylmethoxycarbonyl)amino-5-iodo-4-oxo-butanoic acid tert.butyl ester (1 g, 1.8 .nmol), 2,6-dimethylbenzoic acid (0.5 g, 3.3 mmol) and AgOAc (0.6 g, 3.6 mmol) are dissolved in acetone (25 ml) and refluxed for 1 hr. After filtration and evaporation the crude product is chromatographed (Si02, ether/hexane 3/7) yielding the title compound.
EXAMPLE 71: (3S)-3-Fluorenylmethoxycarbonyl)amino-5(4-
nitrophenoxy)-4-oxo pentanoic acid tert.butyl ester
3S-3-(Fluorenylmethoxycarbonyl)amino-5-iodo-4-oxo-butanoic acid tert.butyl ester (1 g, 1.8 mmol), p-nitrophenol (0.5 g, 3.7 mmol) and K2C03 (0.38 g, 2.8 mmol) are refluxed in acetone (6 ml) for 30 min., CH2C12 added and the organic phase washed with 2N NaHC03. The combined organic phases are dried, evaporated and chromatographed (Si02, EtOAc/hexane 2/8), yielding the title compound as a yellow oil.
EXAMPLE 72: (Z-valyl-alanyl)-(3R,4S)-3-aJiiino-4,5-dihydroxy pentanoic acid ethyl ester a) Ethyl (3R,4S)-3-benzylamino-4,5-(isopropylidenedioxy)
pentanoate (Y. Yamada, Tetrahedron Leters 1983, 24, 3009) and 102 Pd/C in ethanol are shaken at r.t. for 30 mn under H2.
100-7821
Filtration and evaporation of the reaction mixture give ethyl (3R,4S)-3-amino-4,5-(isopropylidenedioxy)pentanoate vhich is used vithout further purification.
b) Z-Val-Ala-OH is dissolved in THF, HOBTHjO and DCC are added at 5°C. After stirring for 20 min. at 5°C, diisopropylethylamine and ethyl (3R,4S)-3-amino-A,5-(isopropylidenedioxy)pentanoate in THF are added. Reaction mixture is stirred overnight at room temperature, filtered, evapored and chromatographed to afford (Z-valyl-alanyl)-(3R,4S)-3-amino-4,5-(isopropyliden-edioxy)pentar.oic acid ethyl ester.
c) Compound 74 b) is dissolved in Ac0H/H20 (75/25) and stirred at 40°C for 4 hours. After evaporation, vater is added and the mixture is extracted vith AcOEt. The combined extracts are vashed vith vater, NaHC03 solution, NaCl solution, dried over Na-SO;, filtered and evaporated, yielding the title compound.
The compounds of formula I their physiologically-hydrolysable and -acceptable esters and amides and their pharmaceutical^ acceptable salts (hereinafter referred to as compounds of the invention) exhibit pharmaceutical activity and are, therefore, useful as pharmaceuticals.
In particular, the compounds of the invention inhibit IL-16 secretion as indicated in the following in vitro test using THP-1 cells and in vivo test methods:
a) 900 ul THP-1 cells (0.5 x 106 cells) together with 100 U Y-interferon/0.9 ml RPMI 1640 medium (containing 2 mM L-glutamine and 5 X heat-inactivated foetal calf serum) are pipetted into 24 veil culture plates. 100 yl of the compound to be tested are then added. After 3 hours at 37 0 C in 5 X C02/95 X air, 10 yl lipopolysaccharide 500 ug/ml is added and
100-7821
the incubation continued for a further 40 hours. Appropriate controls (vith and vithout stimulus, solvent) ar also included. The niedia are then removed and clarified by centri-fugation at 1000 g for 10 min. 1.0 ml digitonin 0.01 % is added to the veils to lyse the cells vhich are loosened by scraping vith a rubber policeman and left at 4 0 C for 10 min. Lactate dehydrogenase measurements are then performed immediately and the samples stored at - 20 0 C until the other determinations can be made. The assays are: IL-10 (medium and lysate), IL-6 (medium), TNF-a (medium), PGE2 (medium and lysate), lactate dehydrogenase (LDH) and DNA (l/sates). IL—10, IL-6 and TNF-a assays are determined using commercially available ELISA kits (Cistron), PGE; is measured using a standard RIA and DNA fluorimetrically using DAPI.
In this test, the compounds of the invention selectively inhibit IL-16 release in concentrations from about 0.01 to 100 uM. In contrast IL-6, TNF-a, PGE2 and DNA levels remain substantially unaffected, and the compounds are non-toxic, since LDH release is unchanged. It has for example been determined that compounds of examples AO and 50 have an IC50 value (concentration of compound vhich inhibits to 502 the release of IL-10) of 1 and 0.1 uM respectively.
LPS-Fever
A LPS-suspension (Sigma, No. L-5886; 100ug/5ml glucose solution/kg s.c.) is injected in male Tuttlingen SD rats (150-160g). 2 hours later the body temperature is measured using a thermistor rectal probe connected to an ELLAB tele-thermometer. After A hours the test compound is administered p.o. 2 hours later (6 hrs after LPS administration) the temperature is measured again. The temperature increment shown by the untreated controls is taken as 1002 and that in
the treated group is expressed as a percentage of this value. The ED50 is the dose causing a 502 inhibition of the temperature increase determined in the control rats. In this test compounds of the invention inhibit the LPS-induced temperature increase vhen administered at a dosage in the range of from 0.001 to 0.1 mg/kg p.o. It has for example been determined that compounds of examples AO and 50 have each an ED50 value of 0.01 mg/kg p.o. and compound of example 51 an ED50 value of 0.05 mg/kg p.o.
c! Carrageenan-Induced Pav Edema in the Rat
50FA male rats, 150-170g body weight, are used for each group. The test compound is administered orally as a suspension in physiological saiine/0.5£ tragacanth 1 hour prior to the carrageenan injection. Carrageenan (0.1ml of a IX suspension in physiological saline) is given by subplantar injection into one hind pav. The swelling of the pav is measured by means of an antiphlogometer according to Kemper & Amelm. A control reading is taken immediately after the injection, and the swelling is measured after 3 and 5 hrs. The mean value of the 3- and 5-hour reading is taken after deduction of the control reading, the values obtained from the treated animals are expressed as a percentage of the value obtained from non-treated controls. The ED50 is the dose causing a 5OX inhibition of the carrageenan-induced swelling after 3 hrs. In this test method compounds of the invention inhibit significantly the carrageenen-induced swelling when administered p.o. at a dosage in the range of from 0.02 to 5 mg/kg. It has for example been determined that compound of example 40 and 50 have an ED50 value of 0.2 and 1 mg/kg p.o. respectively.
100-7821
Compounds of the invention are therefore useful for the treatment of disorders vith an aetiology associated vith or comprising excessive IL-1S release, e.g. in a vide variety of inflammatory states and diseases, for example tissus calcium depletion, degenerative processes in bone and cartilage, e.g. rheumatoid arthritis and osteoarthritis, inflammatory bowel disease, irritable bovel disease, septic shock, psoriasis, asthma, adult respiratory distress syndrome, diabetes type I, osteoporosis of various genesis including e.g. climacteric or post-menopausal osteoporosis as veil as osteoporosis consequential to old age, immobilization or trauma, arteriosclerosis and Alzheimer disease.
For the above uses the required dosage vill of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general hovever, satisfactory results are achieved at daily dosage rates of from about 0.001 to about 100 mg/kg, preferably 0.001 to about 10 mg/kg animal body veight. Suitable daily dosage rates for larger mammals, for example humans, are of the order of from about 0.1 mg to about 1 g/day, conveniently administered once, in divided dosages 2 to 4 x/day, or in sustained release form.
Compounds of Examples 50 and 51 are preferred.
In accordance vith the foregoing the present invention also provides:
a) A method for the treatment of disorders vith an aetiology associated vith or comprising excessive IL-10 release, e.g. as indicated above in a subject in need thereof, vhich method comprises administering to said subject an effective amount of a compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof, or a pharmaceutical^ acceptable salt thereof;
9 /
- 33 - 100-7821
b) A compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical, for example for use as an agent, e.g. in the method as disclosed above.
The compounds of the invention may be administered by any conventional route, in particular nasally, enterally, preferably orally, e.g. in the form of tablets or capsules, or parenterally e.g. in the form of injectable solutions or suspensions or in a suppository form. Unit dosage forms contain, for example from about 25 ug to 500 mg of a compound of the invention.
The compounds of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
Furthermore the present invention also provides:
c) A pharmaceutical composition comprising a compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof or a pharmaceutically acceptable salt thereof, as hereinbefore defined, together vith a pharmaceutically acceptable diluent or carrier therefor. Such compositions may be manufactured in conventional manner. They may comprise up to 99.9X by veight of active ingredient.
24498
34 -
Claims (10)
1. A compound of formula I R-[Aj-A2]n-A3-A4-X-A5 (I) vherein R is hydrogen, an amino protecting group or optionally ring substituted benzyloxy, n is 0 or 1, Aj. is Val, Leu, Ala, lie or trimethylsilyl-Ala, A2 is Phe or Tyr, A3 is a direct bond, Val, Leu, Ala, lie, trimethylsilyl-Ala or a divalent radical of formula (a) vherein ring A is optionally substituted by hydroxy or C1_4alkoxy, A4 is a direct bond or a divalent radical of formula (b) vherein Rx is hydrogen or Ci_4alkyl, and Yi is the residue attaching to the a-carbon atom of an a-amino acid and is optionally protected, -CH2-CH2-N(C1_4alkyl)2, imidazol-2-yl-methyl, benzimidazol-2-yl-methyl, 1H-1,2,4-triazol-3-yl-methyl, pyrazol-3-yl-methyl, indazol-3-yl-methyl or a radical of formula (c) or (d) (a) -N - CH-CO- (b) Ri Yj 244 - 35 - R 3 or (c) (d) vherein each of R2 and R3, independently, is hydrogen, halogen, Ci_4alkyl, CF3 or trityl, at most one of Rj and R3 being H, and each of R4 and R5 independently is hydrogen, Ci_4alkyl, hydroxy, Ci_4alkoxy, CF3, phenyl or halogen, at most one of R4 and R5 being H, or A3 and A4 form together a radical of formula (aa) vherein Yj is as defined above and Rt and Rj, form together -(CH2)B- vherein m is 2, 3, 4 or 5, and i) X is a divalent radical of formula (ej) -NH-CH - CO-N - CH-CO- (aa) Rla R: Y: 6 0 C02 H vherein R6 is H or Ci_4alkyl, 244985 - 36 and A5 is CF3; a radical -CHj-Xi^ vherein X: is 0 or S and Y3 is heteroaryl; a radical -CH2-Y3; or a radical of formulae (k) to (0) R, Ay 10 -CHj-X^CO-Y^, -CHj-XiVO") R 11 (k) (1) Ri 0 -CH2-Xl-( b'T \ Rn (0) wherein Xi is as defined above, Y4 is tri-(C1_4alk.yl)methyl or a residue -( C 1 ring B is pyridyl, ring C is phenyl or pyridyl, each of R7 and R8 independently is Ci_4alkyl, Ci.^alkoxy, CF3, halogen, nitro or cyano, and each of R9, R10 and Rjx independently is nitro, cyano, CF3, carbamoyl, C02R12, -CH=CH-CN or -CHaCHCOjRj2 vherein Rj2 is Ci.salkyl, or X is a divalent radical of formula (e2) - 37 - L 98 :s (e2) wherein Rg is as defined above, vhen A5 is H, or ii) X is a divalent radical of formula (f), (f) wherein Rq is as defined above, and A5 is -Z1-Z2-Y2 wherein each of Z} and Z? independently is a direct bond or an n-amino acid residue and Y2 is nh2» Ci_4alkylamino, di-(Cj_4alkyl)amino or a heterocyclic radical attached by a nitrogen to Z2,or a radical of formula (k) to (0) as defined above, or OR 13 or NR14R15 wherein R13 is Ci-ipalkyi optionally substituted by OH or interrupted by 0 and each of R^4 and R15 is independently hydrogen, Ci_i2a^yl, C5_7cycloalkyl or benzyl, or iii)X is a divalent radical of formula (g) u wherein Rg is as defined above, and A5 is -Zi-Zj-Yj as defined above, or iv) X is a divalent radical of formula (h) or (j) - 38 - 24498 (h) (j) wherein Rg is as defined above, and A5 is a radical of formulae (k) to (o), -CH2-Yj or -CHj-Xi-Yj as defined above, vith the provisos that only one of A3 and A4 can be a direct bond when n is 0, and each of A3 and A4 is other than a direct bond when n is 1, or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form, in salt form or in the form of a complex.
2. A compound of formula I according to claim 1, wherein n is 0, A3 is a direct bond, Val, Leu, Ala, lie or trimethylsilyl-Ala, A4 is as defined in claim 1, or Aj and A4 form together a radical of formula (aa) as defined in claim 1, and i) X is a radical of formula (ex) or (f) and A5 is a radical of formula (k), (1) or (m) as defined in claim 1 wherein Xj is 0, ii)X is a radical of formula (g) and A5 is -Zi-Z2-Y2 as defined in claim 1, or iii) X is a radical of formula (j) and A5 is a radical of formula (k), (1) or (m) as defined in claim 1 wherein Xt is 0. 244985 39 or a physiologically-hydrolysable and -acceptable ester or amide thereof, in tree form, in salt form or in the form of a complex.
3. A compound of formula I according to claim 1 vherein n is 0 and each of A3 and A< is other than a direct bond, or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form, in salt form or in the form of a complex.
4. A compound of formula 1 according to claim 1 or 3 vherein Yj is the residue attaching to the a-carbon atom of an a-amino acid selected from Ala, Leu, His, Phe, Met, Trp, trimethyl-silyl-Ala and optionally side chain protected Arg, Orn and Lys, or Yj is a radical of formula (c), or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form, in salt form or in the form of a complex.
5. A compound of formula I according to claim 1, 3 or 4 vherein X is a radical of formula (ei), (h) or (j), A5 being other than H vhen X is (eO, or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form, in salt form or in the form of a complex.
6. (Benzyloxycarbonyl-valyl-alanyl)-3R-3-amino-4-oxo-5-(2,6-di chlorobenzoyloxy) pentanoic acid ethyl ester; (benzyloxycarbonyl-valyl-alanyl) -3R,S-3-amino-4-oxo-5-(2,6-dichloro benzoyloxy) pentanoic acid ethyl ester; (benzyloxycarbo-nyl-valyl-alanyl)-3R-3-amino-4-oxo-5-(2,6-dichloro-pyridyl-4-carbonyloxy) pentanoic acid ethyl ester; (benzyloxycarbo-nyl-valyl-alanyl)-3R,S-3-amino-4-oxo-5-(2,6-dichlorobenzoyl oxy) pentanoic acid; (benzyloxycarbonyl-valyl-alanyl)-3R,S-3-amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid isopropyl ester; (benzyloxycarbonyl-valyl-alanyl)-3R,S-3- 24498 - 40 - amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid t.-butyl ester; and (benzyloxycarbonyl-valyl-alanyl)-3S--3-amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid in free form, in salt form or in the form of complexes.
7. A process for producing a compound of formula I as defined in claim 1 or a physiologically-hydrolysable and -acceptable ester or amide thereof, which process comprises a) removing at least one protecting group from a compound of formula I in protected form or adding a protecting group R as defined in claim 1 at the N-terminal group of a compound of formula I; or b) converting one compound of formula I into another compound of formula I; or c) coupling together by an amide bond two peptide fragments, each of which contains at least one amino acid in protected or unprotected form and one peptide fragment containing a radical of formula (ei) to (j) as defined in claim 1, the peptide fragments being such that a protected or unprotected peptide having the sequence according to formula I above is obtained and, if necessary, removing the protecting group or groups from a compound of formula I in protected form; or d) for the production of a compound of formula I vherein X is a radical of formula (ei) or (h) and As is a radical of formula (k), (1) or (o) or -CHj-Xi-Yj as defined in claim 1, reacting a compound of formula III R-[Ai-A2]n-A 3-A4-X'-CHj-Z, (III) 244 98 - 41 - vherein R, Aj to At and n are as defined in claim 1, X' is a radical of formula (eO or (h) as defined in claim 1, and Za is a leaving group, vith a corresponding phenol, thiophenol or hx^-pyridine or an acid of formula HX1-CO-Y4 or a functional derivative thereof or HXj-Y3 vherein Xj, Y3 and Y< are as defined in claim 1; or e) for the production of a compound of formula I H R- [ Ax -A2 ] n -Aj -A4 -N (I) C02Ri6 vherein R, Aj to A5 and n are as defined in claim 1 and R16 is a Ci_12 aliphatic or alicyclic residue, oxidizing a compound of formula V H OH R-[Ai-A2]n-A3-A4-N /^A5 C02Ri6 (V) vherein R, Ax to A5, n and R16 are as defined above, and recovering a compound of formula I or a physiologically-hydrolysable and -acceptable ester or amide thereof thus obtained in free or salt form or in the form of a complex.
8. A compound of formula I as defined in claim 1 or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form or in pharmaceutically acceptable salt form, for use as a pharmaceu tical.
9. A pharmaceutical composition comprising a compound of formula^^r 244985 42 I as defined in claim 1 or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form or in pharmaceutically acceptable salt form, together with a pharmaceutically acceptable diluent or carrier therefor.
10. A conpound of formula I as defined in claim 1 or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form, in salt form or in the form of a complex, substantially as hereinbefore described with reference to any one of the foregoing Examples 2, 3 and 6 to 68.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919123326A GB9123326D0 (en) | 1991-11-04 | 1991-11-04 | Improvements in or relating to organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ244985A true NZ244985A (en) | 1995-06-27 |
Family
ID=10703998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ244985A NZ244985A (en) | 1991-11-04 | 1992-11-02 | Peptide compounds, preparation and pharmaceutical compositions thereof |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0611375A1 (en) |
| JP (1) | JPH07500828A (en) |
| AU (1) | AU2885292A (en) |
| CA (1) | CA2116653A1 (en) |
| CZ (1) | CZ106794A3 (en) |
| FI (1) | FI942061A (en) |
| GB (1) | GB9123326D0 (en) |
| HU (1) | HUT68200A (en) |
| IL (1) | IL103612A0 (en) |
| MX (1) | MX9206306A (en) |
| NO (1) | NO941629L (en) |
| NZ (1) | NZ244985A (en) |
| PT (1) | PT101027A (en) |
| SK (1) | SK51194A3 (en) |
| WO (1) | WO1993009135A1 (en) |
| ZA (1) | ZA928511B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| DE69226820T2 (en) * | 1991-06-21 | 1999-05-12 | Merck & Co Inc | Peptidyl derivatives as inhibitors of interleukin-1B converting enzymes |
| AU3666893A (en) * | 1992-02-21 | 1993-09-13 | Merck & Co., Inc. | Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme |
| EP0618223A3 (en) * | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents. |
| US5985838A (en) * | 1993-04-29 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Peptide analogs as irreversible interleukin-1β protease inhibitors |
| CA2122227A1 (en) * | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
| US5462939A (en) * | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
| JPH0789951A (en) * | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | Interleukin-1 beta transfer enzyme inhibitor |
| US5843905A (en) * | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
| JPH0725887A (en) * | 1993-06-04 | 1995-01-27 | Sterling Winthrop Inc | Interleukin-1 beta convertion enzyme inhibitor |
| WO1995005192A1 (en) * | 1993-08-13 | 1995-02-23 | Merck & Co., Inc. | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| US5714484A (en) * | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| US5486623A (en) * | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
| US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5565430A (en) * | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
| GB2292149A (en) * | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| EP0820464A2 (en) * | 1995-03-31 | 1998-01-28 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
| US5798442A (en) * | 1995-04-21 | 1998-08-25 | Merck Frosst Canada, Inc. | Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases |
| EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| WO1997024339A1 (en) * | 1995-12-27 | 1997-07-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
| US5869519A (en) * | 1996-12-16 | 1999-02-09 | Idun Pharmaceuticals, Inc. | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US5968927A (en) * | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| US5877197A (en) * | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6184244B1 (en) * | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6306613B1 (en) | 1997-02-26 | 2001-10-23 | Ciblex Corporation | Modulators of leaderless protein export and methods for identifying and using the same |
| JP2001527390A (en) * | 1997-02-26 | 2001-12-25 | サイブレックス コーポレイション | Inhibitor of leaderless protein export |
| ES2244178T3 (en) | 1998-03-09 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | DERIVATIVES OF 1,2-DIAZEPAN AS INHIBITORS OF THE CONVERTER ENZYME OF INTERLEUQUINA-1 BETA. |
| PT1064298E (en) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inhibitors of caspases |
| US6242422B1 (en) * | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| US7157430B2 (en) | 1998-10-22 | 2007-01-02 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases |
| BR0009610A (en) * | 1999-04-09 | 2002-02-13 | Cytovia Inc | Caspase inhibitors and their use |
| US6525024B1 (en) | 2000-04-17 | 2003-02-25 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
| EP2241328A1 (en) | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| PE20011350A1 (en) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE) |
| WO2002022611A2 (en) * | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| BRPI0508609B8 (en) | 2004-03-12 | 2021-05-25 | Vertex Pharma | processes and intermediaries |
| CN1980658A (en) | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | Treatment of diseases using ICE inhibitors |
| CN101979403A (en) * | 2010-09-13 | 2011-02-23 | 沈陵陵 | Novel broad caspase inhibitor and preparation method and application thereof |
| EP2635907A4 (en) | 2010-11-05 | 2014-04-16 | Univ Brandeis | Ice cleaved alpha-synuclein a biomarker |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| CA3003820A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7775991A (en) * | 1990-04-04 | 1991-10-30 | Immunex Corporation | Interleukin 1beta protease |
-
1991
- 1991-11-04 GB GB919123326A patent/GB9123326D0/en active Pending
-
1992
- 1992-10-29 JP JP5508146A patent/JPH07500828A/en active Pending
- 1992-10-29 HU HU9401303A patent/HUT68200A/en active IP Right Revival
- 1992-10-29 SK SK511-94A patent/SK51194A3/en unknown
- 1992-10-29 CA CA002116653A patent/CA2116653A1/en not_active Abandoned
- 1992-10-29 AU AU28852/92A patent/AU2885292A/en not_active Abandoned
- 1992-10-29 EP EP92922580A patent/EP0611375A1/en not_active Withdrawn
- 1992-10-29 WO PCT/EP1992/002472 patent/WO1993009135A1/en not_active Application Discontinuation
- 1992-10-29 CZ CZ941067A patent/CZ106794A3/en unknown
- 1992-11-02 IL IL103612A patent/IL103612A0/en unknown
- 1992-11-02 PT PT101027A patent/PT101027A/en not_active Application Discontinuation
- 1992-11-02 NZ NZ244985A patent/NZ244985A/en unknown
- 1992-11-03 MX MX9206306A patent/MX9206306A/en unknown
- 1992-11-04 ZA ZA928511A patent/ZA928511B/en unknown
-
1994
- 1994-05-03 NO NO941629A patent/NO941629L/en unknown
- 1994-05-04 FI FI942061A patent/FI942061A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA928511B (en) | 1994-05-04 |
| JPH07500828A (en) | 1995-01-26 |
| PT101027A (en) | 1994-02-28 |
| CZ106794A3 (en) | 1994-12-15 |
| GB9123326D0 (en) | 1991-12-18 |
| FI942061A0 (en) | 1994-05-04 |
| AU2885292A (en) | 1993-06-07 |
| EP0611375A1 (en) | 1994-08-24 |
| HUT68200A (en) | 1995-05-29 |
| SK51194A3 (en) | 1995-02-08 |
| NO941629L (en) | 1994-07-04 |
| NO941629D0 (en) | 1994-05-03 |
| WO1993009135A1 (en) | 1993-05-13 |
| MX9206306A (en) | 1993-05-01 |
| IL103612A0 (en) | 1993-04-04 |
| CA2116653A1 (en) | 1993-05-13 |
| FI942061A (en) | 1994-05-04 |
| HU9401303D0 (en) | 1994-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ244985A (en) | Peptide compounds, preparation and pharmaceutical compositions thereof | |
| US4918105A (en) | Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present | |
| US4885283A (en) | Phosphinic acid derivatives | |
| US5036054A (en) | Renin inhibitors containing alpha-heteroatom amino acids | |
| US4728638A (en) | Somatostatine derivatives | |
| JPS62230757A (en) | Hydroxylamine derivative | |
| EP0618223A2 (en) | Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents | |
| HUT68563A (en) | Peptide analogs as irreversible interleukin-1-beta protease enzim inhibitors, pharmaceutical compositions containing the said peptidanalogs and process to prepare them | |
| JPH04211095A (en) | Novel dipeptide, preparation thereof and use thereof as renin inhibitor in medication | |
| KR100622709B1 (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors | |
| HU186983B (en) | Process for preparing new 3-amino-5-pregnene derivatives and salts thereof | |
| US5646121A (en) | Pseudopeptides with antiviral activity | |
| JP4171423B2 (en) | Process for the preparation of high purity perindopril and useful intermediates for synthesis | |
| EP0074787B1 (en) | Renally active dipeptides | |
| SU908246A3 (en) | Process for producing tetrapeptide derivatives or their salts | |
| JPS5819669B2 (en) | Novel bioactive peptide compounds and their production methods | |
| HUT52525A (en) | Process for producing retroviral proteaz-inhibitors and pharmaceutical compositions containing them as active components | |
| US4420490A (en) | Substituted phenylacetic acid amide compounds | |
| US4387049A (en) | Adamantyl containing peptides | |
| US5985838A (en) | Peptide analogs as irreversible interleukin-1β protease inhibitors | |
| KR880002594B1 (en) | Process for preparing n-carboxyalkylproline-containing tripeptides | |
| US5166154A (en) | Imidazo[1,2-a]piperazines | |
| US4456594A (en) | N-Carboxyalkylproline-containing tripeptides | |
| US4247543A (en) | Organic compounds | |
| US4452783A (en) | Derivatives of substituted phenylacetic acids and compositions containing them |